Development of a Novel Acoustic Resuscitation Monitor

描述（由申请人提供）：目前，几乎一半的创伤死亡可直接或间接归因于失血性休克，在美国每年有超过5万人死亡，造成数千亿美元的经济损失。Active Signal Technologies提出开发一种声学复苏监视器（ARM），用于实时无创评估全身灌注，最终目标是开发一种可以在现场连续监测休克和复苏的设备。由于没有这样的设备存在，而且目前的灌注试验有明显的滞后时间，因此ARM可以显著改善患者的预后，降低住院（I期）和现场（II期）的成本。ARM技术基于Active Signal的脑声学监测器（BAM），在500多名创伤和100多名中风患者的脑灌注研究中得到了有效证明。在I期，Active Signal与马里兰大学休克创伤中心将对大约100名患者进行5次数据收集的可行性测试。具体目的是确定使用脉冲波形特征的ARM指示的血管收缩与当前临床指标测量的全身灌注之间的关系，并重新配置BAM以监测3个动脉树水平的血管收缩。

DESCRIPTION (provided by applicant): Currently almost half of all trauma mortality is directly or indirectly attributable to hemorrhagic shock, accounting for more than 50,000 deaths yearly in the U.S. and hundreds of billions of dollars in economic costs. Active Signal Technologies proposes to develop an Acoustic Resuscitation Monitor (ARM) for enabling non-invasive assessment of systemic perfusion in real time, with the ultimate goal of developing a device that can continuously monitor shock and resuscitation in the field. As no such device exists and current perfusion tests have significant lag time, ARM can significantly improve patient outcome and lower costs both for in-hospital (Phase I) and field (Phase II) settings. The ARM technology is based on Active Signal's Brain Acoustic Monitor (BAM) - demonstrated effectively in brain perfusion studies on more than 500 trauma and 100 stroke patients. In Phase I Active Signal with the University of Maryland Shock Trauma Center will conduct feasibility tests on approximately 100 patients with 5 data collection times. Specific aims are to determine the relationship between vasoconstriction as indicated by ARM using pulse-waveform characteristics and systemic perfusion measured by current clinical metrics, and to reconfigure the BAM to monitor vasoconstriction at 3 arterial tree levels.